Patent Terminology

Abandonment: An application that has been declared abandoned is dead and no longer pending. Abandonment occurs under several circumstances. The most common reason is when the USPTO does not receive a response from an applicant to an Office Action letter within 6 months from the date the Office action letter was mailed. Another instance is when the USPTO does not receive a Statement of Use (or request for an extension of time to file a statement of use) from an applicant within 6 months from the issuance of a Notice of Allowance). Applications abandoned for failure to respond to an Office Action or a Notice of Allowance can be revived or reinstated in certain circumstances.

Absolute Novelty: A system whereby any prior publication or prior use anywhere in the world destroys the novelty of a patent.

Acquisition: The Acquiring, or takeover, of a company by buying up the company shares giving the buyer voting control of the company.

Active inducement to infringe: One may be held liable for patent infringement as a result of actively encouraging another to infringe if such other does infringe, even though the inducer has not made, used, sold, offered for sale, or imported the patented invention.

Advisory action: An official action issued by the US examiner when a final rejection is being maintained.

AIPA: American Inventors Protection Act of 1999.

AIPLA: American Intellectual Property Law Association.

AIPPI: The International Association for the Protection of Intellectual Property.

Alternative dispute resolution: Alternatives to the court system to resolve disputes. This usually refers to mediation or arbitration. May include mechanisms set out in contracts.

ANDA, Abbreviated New Drug Application, is the process of obtaining approval to market a generic drug. An ANDA contains information demonstrating that the generic drug is bioequivalent to the brand-name product and certification that the generic drug does not infringe on any patent for the brand-name product listed in the Orange Book or certification that the listed patents are invalid.

Anticipation: Prior art which destroys the novelty of a claim by fully describing something falling within it.

Apparatus claim: This refers to that part of a patent document called the Claims. An apparatus Claim provides a structural description of a piece of equipment that is embraced by the expression “machine” in the definition of patentable subject matter in the US Patent Statute. Drawings of the apparatus are essential.

Appeal brief: A summary of the arguments why the invention should be patentable, submitted to the board of appeals.

applicant1: In the US applicants must be individuals. An application for patent is filed under 35 USC 111(a).

Apportionment of Profit: A measure of damages in patent-infringement litigation. Apportionment generally refers to dividing the profits on the sale of a particular piece of apparatus or a product according to the percentage of cost or sale price attributable to the patented invention. Where the whole of the product is covered by the patent, or where the patented component contributes all of the market value, apportionment of profit is not necessary.

Argument: The process by which a lawyer or other person tries to persuade the court, based on the record, to find for his side. The Attorney’s Canon of Ethics (sic) require there be some basis in the record for such arguments.

Assignee: The person or company to whom ownership of the patent is transferred. Usually by assignment in writing. Note exception…Matrimonial Property Act.

Assignment – in intellectual property an assignment is a legal transfer of ownership or usage rights from one entity to another.

assignment: A transfer of ownership of a patent application or patent from one entity (assignor) to another (assignee). All assignments should be recorded with the USPTO Assignment Services Division to maintain clear title to pending patent applications and patents.

Automatic prohibition: 30-month stay is the automatic prohibition of FDA action on an ANDA with a Paragraph IV certification if the brand-name company files a patent infringement suit against the generic applicant within 45 days.